Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma
Abstract
1. Introduction
2. Materials and Methods
2.1. Subjects and Tissue Samples
2.2. Immunohistochemistry
2.3. Assessment of Immunohistochemical Staining
2.4. Statistical Analysis
3. Results
3.1. Patients and Tissue Samples
3.2. PD-L1 in Dysplasia and Comparison with Normal Epithelium and Metaplasia
3.3. PD-L1 and CD8 Evaluation in Dysplasia
3.4. PD-L1 and CD8 Expression and Degree of Dysplasia
3.5. P D-L1 and CD8 Expression and Medical History of Squamous Cell Carcinoma
4. Discussion
Author Contributions
Funding
Acknowledgments
Consent to Participate
Conflicts of Interest
References
- Merrick, D.T.; Gao, D.; Miller, Y.E.; Keith, R.L.; Baron, A.E.; Feser, W.; Kennedy, T.C.; Blatchford, P.J.; Braudrick, S.; Hirsch, F.R.; et al. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev. Res. 2016, 9, 96–104. [Google Scholar] [CrossRef] [PubMed]
- George, P.J.; Banerjee, A.K.; Read, C.A.; O’Sullivan, C.; Falzon, M.; Pezzella, F.; Nicholson, A.G.; Shaw, P.; Laurent, G.; Rabbitts, P.H. Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax 2007, 62, 43–50. [Google Scholar] [CrossRef] [PubMed]
- Mok, T.S.K.; Wu, Y.L.; Kudaba, I.; Kowalski, D.M.; Cho, B.C.; Turna, H.Z.; Castro, G.; Srimuninnimit, V.; Laktionov, K.K.; Bondarenko, I.; et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet 2019. [Google Scholar] [CrossRef]
- Lantuejoul, S.; Adam, J.; Girard, N.; Duruisseaux, M.; Mansuet-Lupo, A.; Cazes, A.; Rouquette, I.; Gibault, L.; Garcia, S.; Antoine, M.; et al. Tests immunohistochimiques PD-L1 dans les cancers du poumon non à petites cellules : Recommandations par le groupe PATTERN de pathologistes thoraciques. Ann. Pathol. 2018. [Google Scholar] [CrossRef] [PubMed]
- Adam, J.; Forest, F.; Mansuet-Lupo, A.; Ilié, M. Recent updates regarding PD-L1 testing in non-small cell lung carcinoma. Ann. Pathol. 2019, 39, 303–304. [Google Scholar] [CrossRef] [PubMed]
- Merrick, D.T.; Edwards, M.G.; Franklin, W.A.; Sugita, M.; Keith, R.L.; Miller, Y.E.; Friedman, M.B.; Dwyer-Nield, L.D.; Tennis, M.A.; O’Keefe, M.C.; et al. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018, 78, 4971–4983. [Google Scholar] [CrossRef]
- Mascaux, C.; Angelova, M.; Vasaturo, A.; Beane, J.; Hijazi, K.; Anthoine, G.; Buttard, B.; Rothe, F.; Willard-Gallo, K.; Haller, A.; et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 2019, 571, 1–6. [Google Scholar] [CrossRef]
- Gonçalves, A.S.; Mosconi, C.; Jaeger, F.; Wastowski, I.J.; Aguiar, M.C.F.; Silva, T.A.; Ribeiro-Rotta, R.F.; Costa, N.L.; Batista, A.C. Overexpression of immunomodulatory mediators in oral precancerous lesions. Hum. Immunol. 2017, 78, 752–757. [Google Scholar] [CrossRef]
- Mezache, L.; Paniccia, B.; Nyinawabera, A.; Nuovo, G.J. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod. Pathol. 2015, 28, 1594–1602. [Google Scholar] [CrossRef]
- Lee, M.-H.; Yanagawa, J.; Li, R.; Walser, T.C.; Krysan, K.; Wang, G.; Goldman, J.W.; Garon, E.B.G.; Zeng, G.; Sharma, S.; et al. Increased PD-L1 expression in KRAS mutated premalignant human bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation. J. Immunother. Cancer 2015, 3, 2–3. [Google Scholar] [CrossRef]
- Beane, J.E.; Mazzilli, S.A.; Campbell, J.D.; Duclos, G.; Krysan, K.; Moy, C.; Perdomo, C.; Schaffer, M.; Liu, G.; Zhang, S.; et al. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat. Commun. 2019, 10. [Google Scholar] [CrossRef]
- Teixeira, V.H.; Pipinikas, C.P.; Pennycuick, A.; Lee-Six, H.; Chandrasekharan, D.; Beane, J.; Morris, T.J.; Karpathakis, A.; Feber, A.; Breeze, C.E.; et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat. Med. 2019, 25, 517–525. [Google Scholar] [CrossRef] [PubMed]
- Acosta-Gonzalez, G.; Ouseph, M.; Lombardo, K.; Lu, S.; Glickman, J.; Resnick, M.B. Immune environment in serrated lesions of the colon: Intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum. Pathol. 2019, 83, 115–123. [Google Scholar] [CrossRef] [PubMed]
- Clément-Duchêne, C.; Alla, F.; Gauchotte, G.; Marie, B.; Carnin, C.; Menard, O.; Vignaud, J.-M.; Martinet, Y. Is there a relationship between the presence of lung mucosa preinvasive lesions and lung cancer incidence? Influence of tobacco consumption. Lung Cancer 2014, 84, 134–138. [Google Scholar] [CrossRef] [PubMed]
- Hatam, L.J.; DeVoti, J.A.; Rosenthal, D.W.; Lam, F.; Abramson, A.L.; Steinberg, B.M.; Bonagura, V.R. Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression. Clin. Cancer Res. 2012, 18, 1925–1935. [Google Scholar] [CrossRef] [PubMed]
- Tsao, M.S.; Kerr, K.M.; Kockx, M.; Beasley, M.-B.; Borczuk, A.C.; Botling, J.; Bubendorf, L.; Chirieac, L.; Chen, G.; Chou, T.-Y.; et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J. Thorac. Oncol. 2018, 13, 1302–1311. [Google Scholar] [CrossRef] [PubMed]
- Torlakovic, E.; Lim, H.J.; Adam, J.; Barnes, P.; Bigras, G.; Chan, A.W.H. “Interchangeability” of PD-L1 immunohistochemistry assays: A meta-analysis of diagnostic accuracy. Nature 2020, 33, 4–17. [Google Scholar] [CrossRef] [PubMed]
- Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar] [CrossRef]
- Sousa, V.; Santo, J.E.; Silva, M.; Cabral, T.; Alarcão, A.M.; Gomes, A.; Couceiro, P.; Carvalho, L. EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: An immunohistochemical and genetic study. Virchows Arch. 2011, 458, 571–581. [Google Scholar] [CrossRef]
- Yagyuu, T.; Hatakeyama, K.; Imada, M.; Kurihara, M.; Matsusue, Y.; Yamamoto, K.; Obayashi, C.; Kirita, T. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. Oral Oncol. 2017, 68, 36–43. [Google Scholar] [CrossRef]
- Zhang, C.; Zhang, J.; Xu, F.P.; Wang, Y.G.; Xie, Z.; Su, J.; Dong, S.; Nie, Q.; Shao, Y.; Zhou, Q.; et al. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma. J. Thorac. Oncol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Thunnissen, E.; Kerr, K.M.; Dafni, U.; Bubendorf, L.; Finn, S.P.; Soltermann, A.; Biernat, W.; Cheney, R.; Verbeken, E.; Warth, A.; et al. Programmed Death-Ligand 1 Expression Influenced by Tissue Sample Size. Scoring Based on Tissue Microarrays’ and Cross-Validation With Resections, in Patients With, Stage I-III, Non-Small Cell Lung Carcinoma of the European Thoracic Oncology Platform Lungscape Cohort. Mod. Pathol. 2020, 33, 792–801. [Google Scholar] [CrossRef] [PubMed]
Availability of Data and Material: All data and material are available on request. |
PD-L1 Expression by Dysplastic Cells | |||
---|---|---|---|
Not Expressed, n (%) | Expressed, n (%) | p | |
Age | 0.36 | ||
> 60 years old | 3 (12.5) | 4 (16.7) | |
≤ 60 years old | 12 (50) | 5 (20.8) | |
CD8 expressing cells localization | 0.99 | ||
Sub-mucosal | 6 (25) | 4 (16.7) | |
Intra-epithelial | 1 (4.2) | 0 (0) | |
Sub-mucosal and intra-epithelial | 6 (25) | 4 (16.7) | |
No expression | 1 (4.2) | 0 (0) | |
Not assessable | 1 (4.2) | 1 (4.2) | |
PDL-1 expression by intra-epithelial-immune cells | 0.21 | ||
PD-L1 expressed | 9 (37.5) | 3 (12.5) | |
PD-L1 not expressed | 5 (20.8) | 7 (29.2) | |
PDL-1 expression by sub-mucosal immune cells | 0.65 | ||
PD-L1 expressed | 4 (16.7) | 4 (16.7) | |
PD-L1 not expressed | 8 (33.3) | 4 (16.7) | |
Not assessable | 2 (8.3) | 2 (8.3) |
Mean Age | Pack-Years | Moderate Dysplasia, n (%) | Severe Dysplasia, Carcinoma in Situ, n (%) | p | No Medical History of Squamous Cell Carcinoma, n (%) | Medical History of Squamous Cell Carcinoma, n (%) | Unknown, n (%) | p | |
---|---|---|---|---|---|---|---|---|---|
PD-L1 expression by dysplastic cells | 1 | 1 | |||||||
0% | 64+/−3 | 46+/−7 | 6 (25) | 9 (37) | 6 (25) | 8 (33) | 1 (4) | ||
≥ 1% | 63+/−6 | 41+/−8 | 4 (17) | 5 (21) | 4 (17) | 4 (17) | 1 (4) | ||
PD-L1 expression by intraepithelial immune cells | 0.68 | 0.67 | |||||||
Not expressed | 6 (25) | 6 (25) | 6 (25) | 5 (21) | 0 (0) | ||||
Expressed | 62+/−3 | 47+/−8 | 4 (17) | 8 (33) | 4 (17) | 7 (17) | 0 (0) | ||
PD-L1 expression by sub-mucosal immune cells | 65+/−2 | 44+/−8 | 0.20 | 0.65 | |||||
Not expressed | 68+/−1 | 36+/−7 | 7 (29) | 5 (21) | 4 (17) | 7 (29) | |||
Expressed | 62+/−3 | 53+/−1 | 2 (8) | 6 (25) | 4 (17) | 4 (17) | |||
Not assessable | 60 | 30 | 1 (4) | 3 (12) | 2 (8) | 1 (4) | 1 | ||
Previous or following squamous cell carcinoma | 0.66 | ||||||||
No | 66+/−2 | 61+/−9 | 5 (21) | 5 (21) | |||||
Yes | 62+/−3 | 33+/−5 | 4 (17) | 8 (33) | |||||
Unknown | 62+/−2 | 25+/−5 | 1 (4) | 1 (4) | |||||
CD8 expressing cells localization | 0.78 | 0.044 | |||||||
Sub-mucosal | 64+/−2 | 55+/−8 | 4 (17) | 6 (25) | 6 (25) | 3 (12) | 1 (4) | ||
Intra-epithelial | 65 | 20 | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 1 (4) | ||
Sub-mucosal and intra-epithelial | 67+/−2 | 33+/−8 | 4 (17) | 6 (25) | 2 (8) | 8 (33) | 0 (0) | ||
No expression | 61 | 40 | 0 | 1 (4) | 1 (4) | 0 (0) | 0 (0) | ||
Not assessable | 48+/−10 | 65+/−15 | 1 (4) | 1 (4) | 1 (4) | 1 (4) | 0 (0) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Laville, D.; Casteillo, F.; Yvorel, V.; Tiffet, O.; Vergnon, J.-M.; Péoc’h, M.; Forest, F. Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma. Diagnostics 2020, 10, 503. https://doi.org/10.3390/diagnostics10070503
Laville D, Casteillo F, Yvorel V, Tiffet O, Vergnon J-M, Péoc’h M, Forest F. Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma. Diagnostics. 2020; 10(7):503. https://doi.org/10.3390/diagnostics10070503
Chicago/Turabian StyleLaville, David, Francois Casteillo, Violaine Yvorel, Olivier Tiffet, Jean-Michel Vergnon, Michel Péoc’h, and Fabien Forest. 2020. "Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma" Diagnostics 10, no. 7: 503. https://doi.org/10.3390/diagnostics10070503
APA StyleLaville, D., Casteillo, F., Yvorel, V., Tiffet, O., Vergnon, J.-M., Péoc’h, M., & Forest, F. (2020). Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma. Diagnostics, 10(7), 503. https://doi.org/10.3390/diagnostics10070503